Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter

被引：6
作者：
Businello, Gianluca [1 ]
Angerilli, Valentina [1 ]
Lonardi, Sara [2 ]
Bergamo, Francesca [2 ]
Valmasoni, Michele [3 ]
Farinati, Fabio [3 ]
Savarino, Edoardo [3 ]
Spolverato, Gaya [3 ]
Fassan, Matteo [1 ,2 ]
机构：
[1] Univ Padua, Dept Med DIMED, Padua, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Veneto Inst Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
来源：
UPDATES IN SURGERY | 2023年 / 75卷 / 02期
关键词：
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Biomarkers; Immunohistochemistry; ADVANCED GASTRIC-CANCER; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; HER2; STATUS; PHASE-II; MICROSATELLITE INSTABILITY; GASTROESOPHAGEAL CANCER;
D O I：
10.1007/s13304-022-01330-5
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
引用
收藏
页码：291 / 303
页数：13
相关论文
共 50 条
  • [21] Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma
    Taenzer, Marc
    Liebl, Magdalena
    Quante, Michael
    PHARMACOLOGY & THERAPEUTICS, 2013, 140 (02) : 133 - 147
  • [22] Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma
    Saurabh, Animesh
    Raphael, Vandana
    Dey, Biswajit
    Harris, Caleb
    Jagtap, Vikas
    Das, Umesh
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2021, 12 (SUPPL 1) : 144 - 151
  • [23] Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date
    Wheelden, Megan
    Yee, Nelson S.
    ONCOTARGETS AND THERAPY, 2020, 13 : 7459 - 7465
  • [24] Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China
    Zhang, Jingdong
    Wang, Guangyu
    Xie, Xianhe
    Pan, Wensheng
    Dong, Qian
    Zhang, Nianhai
    Dong, Jie
    Zhou, Li
    Zhou, Chan
    Li, Jinnan
    Segall, Grace
    Zhang, Yanqiao
    FUTURE ONCOLOGY, 2025, : 1179 - 1188
  • [25] Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma
    Dhakras, Purabi
    Uboha, Nataliya
    Horner, Vanessa
    Reinig, Erica
    Matkowskyj, Kristina A.
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 5
  • [26] HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
    Ling Shan
    Jianming Ying
    Ning Lu
    Diagnostic Pathology, 8
  • [27] Targeted and Immunotherapy Approaches inHER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
    Radford, Maluki
    Abushukair, Hassan
    Hentzen, Stijn
    Cavalcante, Ludimila
    Saeed, Anwaar
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (03) : 150 - 157
  • [28] Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma
    Nakayama, I.
    Takahari, D.
    Chin, K.
    Wakatsuki, T.
    Takamatsu, M.
    Yamamoto, N.
    Ogura, M.
    Ooki, A.
    Fukuda, K.
    Osumi, H.
    Fukuoka, S.
    Shinozaki, E.
    Yamaguchi, K.
    ESMO OPEN, 2023, 8 (04)
  • [29] Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis
    Kundel, Yulia
    Sternschuss, Michal
    Moore, Assaf
    Perl, Gali
    Brenner, Baruch
    Goldvaser, Hadar
    CANCER MEDICINE, 2020, 9 (20): : 7613 - 7625
  • [30] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions
    Richards, Donald A.
    Boehm, Kristi A.
    Anthony, Stephen P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) : 1059 - 1068
12345